A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.

Trial Profile

A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Ciclosporin (Primary) ; Omeprazole (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms IIT
  • Sponsors Perle Bioscience
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Apr 2016 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 23 Jun 2015 As per a Perle Biosciences media release, the trial has been initiated. Seven designated trial sites are located within Italy, with two additional sites to be scheduled outside of Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top